Charles J. Homcy
Co-Founder, Chairman of Pharmaceuticals & Lead DirectorDr. Charles J. Homcy, M.D., is a Co-Founder of Marea Therapeutics, Inc. and serves as Member of Clinical Scientific Advisory Board since January 2025. Dr. Homcy is a Co-Founder of BridgeBio Pharma, Inc. He has been an Independent Director of BridgeBio Pharma, Inc. since November 2018 and as its Chairman of Pharmaceuticals since February 2019. Prior to that, Dr. Homcy served as the president of research and development at Millennium Pharmaceuticals, Inc. (currently, Takeda Oncology), a biopharmaceutical company, following its acquisition of COR Therapeutics, Inc. in 2002. Dr. Homcy serves as Director of Ambys Medicines, Inc. Dr. Homcy has been Independent Lead Director of BridgeBio Pharma, Inc. since February 2020. He has been Independent Director of Population Health Investment Co., Inc. He served as Partner of Third Rock Ventures, LLC from September 2010 to October 2019. Dr. Homcy had been an Advisor of MyoKardia, Inc. since March 17, 2017. He founded Global Blood Therapeutics, Inc. in 2011 and served as its Advisor. He serves as a Scientific Advisor of Boston Millennia Partners. He served as a Venture Partner of Third Rock Ventures, LLC since 2010. He joined the Third Rock Ventures, LLC in 2010. Dr. Homcy has significant experience building and leading successful biotech companies and has played an integral role in the launching and building of several portfolio companies. He served as a Consultant of Cytokinetics, Incorporated. Dr. Homcy served as the Chief Executive Officer and President of Portola Pharmaceuticals Inc., from November 2003 to May 1, 2010. He co-founded Portola Pharmaceuticals Inc., in 2003 and also served as its Co-Chairman since March 2010 until May 2013. He served as the Interim Chief Executive Officer of MyoKardia, Inc. until October 30, 2013. He served as a Senior Research & Development Advisor of Millennium Pharmaceuticals Inc., from January 2003 to November 2003 and also served as its President of Research and Development from February 2002 to December 2002. He served as an Executive Vice President of Research and Development at COR Therapeutics Inc., since March 1995. He served as the President of the Medical Research Division at American Cyanamid-Lederle Laboratories from 1994 to March 1995. He served as an Executive Director of the Cardiovascular and Central Nervous System Research Section at Lederle Laboratories from 1990 to 1994. Dr. Homcy served as the Chairman of CytomX Therapeutics, Inc. until March 6, 2012 and also served as its Director. He was a Director of Global Blood Therapeutics, Inc. from February 2011 to June 19, 2019. He has been a Director of Kosan Biosciences Incorporated since April 2003. He served as an Independent Director of Pliant Therapeutics Inc. since July 2015 until June 16, 2022. He has been a Director of Cephalon, Inc. since March 10, 2011. He had been an Independent Director of Portola Pharmaceuticals, Inc. since September 2003 until March 2019. He has been a Director of Tinea Pharmaceuticals, Inc. since October 2011. Dr. Homcy serves as a Trustee of Johns Hopkins University. He served as a Director of CytomX Therapeutics, LLC. Dr. Homcy served as a Director of Millennium Pharmaceuticals since December 2002. He served as a Director of MyoKardia, Inc. since June 2012 until March 2017. He served as a Director of Geron Corporation from July 19, 2005 to May 11, 2011. He served as a Director of Cytokinetics Inc., from February 2003 to July 1, 2008. He served as a Member of Scientific Advisory Board at Cytokinetics, Incorporated until April 27, 2017. Dr. Homcy served as a Director of COR Therapeutics Inc., from January 1998 to 2002. He served as a Director of Ikaria, Inc. and Predix Pharmaceuticals Inc. He serves on the Board of GBT. Dr. Homcy served as Clinical Professor of Medicine at the University of California’s San Francisco (UCSF) Medical School and an attending Physician at the San Francisco VA Hospital from 1997 to 2008. From 1991 to 1995, Dr. Homcy served as Clinical Professor of Medicine at The Presbyterian Hospital, College of Physicians and Surgeons, at Columbia University. Dr. Homcy was member of the Cardiac Unit at Massachusetts General Hospital and an Associate Professor of Medicine at Harvard Medical School from 1979 to 1990. He served as Non-Employee Chairman of the Board of Maze Therapeutics, Inc. since June 2018 until October 6, 2025 and is its Director. He served on the Editorial Boards of a number of publications including Circulation Research, American Journal of Physiology and Trends in Cardiovascular Medicine. Dr. Homcy is a co-founder of Relay Therapeutics, Inc., Pliant Therapeutics Inc. and Marea Therapeutics. Dr. Homcy is the author of over 135 original publications in the field of molecular and clinical cardiology. He holds an M.D. and a A.B. in Biology from the Johns Hopkins University in Baltimore and is an Emeritus Trustee.
Positions
- Company NameBridgeBio Pharma, Inc.Stock CodeBBIOPositionCo-Founder, Chairman of Pharmaceuticals & Lead DirectorColleagues
- NKNeil KumarCo-Founder, CEO & Director
- TTThomas TrimarchiCFO & President
- CJCharles J. HomcyCo-Founder, Chairman of Pharmaceuticals & Lead Director
- FPFrank P. McCormickCo-Founder, Chairman of Oncology & Director
- MMMaricel M. ApuliChief Accounting Officer
- AJAli J. SatvatIndependent Director
- FHFred HassanLead Independent Director
- Company NameMaze Therapeutics, Inc.Stock CodeMAZEPositionDirectorColleagues
- JVJason V. ColomaCEO & Director
- HHHerve HoppenotChairman of the Board
- MTMisbah TahirCFO & Principal Accounting Officer
- HSHarold S. BernsteinPresident of Research & Development and Chief Medical Officer
- VVVipin VijayakumarSenior Vice President of Technology and Business Operations
- MHMaarten HoekChief Scientific Officer
- DKDaniel K. SpiegelmanIndependent Non-Employee Director
- JEJonathan E. LimIndependent Non-Employee Director
